Powder: -20°C for 3 years | In solvent: -80°C for 1 year
CXL-1020 是一种硝酰 (HNO) 前体药物。CXL-1020 改善舒张异常大鼠的心肌收缩性/舒张性和 Ca2+循环。CXL-1020 在犬模型中诱导血管舒张并改善心脏功能。CXL-1020 已被用于研究收缩期心力衰竭和稳定期心力衰竭。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
产品描述 | CXL-1020, a nitroxyl (HNO) prodrug, enhances cardiac inotropy/lusitropy and Ca 2+ cycling in rats exhibiting abnormal relaxation, induces vasorelaxation, and augments cardiac function in canine models. It has been investigated for its potential in treating systolic and stable heart failure [1]. |
体内活性 | CXL-1020 (100 μg/kg/min; infusion for 30 min) ameliorates hemodynamics and cardiac function and enhances both diastolic and systolic performance in mice [1]. CXL-1020 (3 and 10 mg/kg/min; 4-hour intravenous infusion) improves left ventricular systolic and diastolic function in dogs with advanced heart failure [2]. Animal Model: Adult male Sprague-Dawley rats (250-350 g; induced cardiac dysfunction by isoproterenol) [1] Dosage: 100 μg/kg/min Administration: For 30 min Result: Improved hemodynamics and cardiac function in normal rats, and enhanced both diastolic and systolic performance in cardiac dysfunction mice. Animal Model: Dogs (coronary microembolization-induced heart failure) [2] 3 and 10 mg/kg/min Dosage: 3 and 10 mg/kg/min Administration: 4-hour intravenous infusion Result: Decreased systolic aortic pressure (AoP) modestly; significantly increased EF and deceleration time of early mitral inflow velocity (DT) and significantly lowered left ventricular (LV) end-systolic volume (ESV), LV end-diastolic pressure (EDP) and end-diastolic wall stress (EDWS) in a dose-dependent manner. |
分子量 | 251.28 |
分子式 | C7H9NO5S2 |
CAS No. | 950834-06-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
CXL-1020 950834-06-7 Inhibitor inhibitor inhibit